NEW YORK (TheStreet) -- Shares of NantKwest Inc (NK) - Get NantKwest, Inc. Report were surging to trade at $36.49 in afternoon trading Tuesday, as the clinical-stage immunotherapy company makes its initial public offering debut on the Nasdaq.
The company priced its IPO of 8.288 million shares of its common stock at a price to the public of $25 a piece, raising $207 million.
Initially the company planned to offer 7 million shares at a price range of between $20 to $23 a share.
NantKwest has granted the underwriters a 30-day option to buy an additional 1,243,200 shares of its common stock.
In addition, NantKwest is selling 680,000 shares of its common stock in a separate private placement to Celgene Corp (CELG) - Get Celgene Corporation Report, an existing stockholder, at $25 per share.
BofA Merrill Lynch (BAC) - Get Bank of America Corp Report, Citigroup Global Markets (C) - Get Citigroup Inc. Report, Jefferies (JEF) - Get Jefferies Financial Group Inc. Report and Piper Jaffray (PJC) - Get Piper Jaffray Companies Report are acting as joint book-running managers for the offering.
Calif.-based NantKwest, formerly Conkwest, is a clinical-stage immunotherapy company focused on using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases.
NK Price data by YCharts